October 1, 2022 Perspectives on Drug Development in Autosomal Recessive Polycystic Kidney Disease Autosomal recessive polycystic kidney disease (ARPKD) is a rare hepatorenal fibrocystic disease that often presents prenatally
October 1, 2022 Perspectives on Drug Development in Early ADPKD The Critical Path Institute’s Polycystic Disease Outcomes Consortium, including key stakeholders (patients, medical experts
September 29, 2022 eCOA Consortium Announces New Article for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Evaluating the Use of Backup Solutions for ePRO Systems” has been publ
September 27, 2022 Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation Board names Dr. Daniel Jorgensen as Chief Executive Officer TUCSON, Ariz., Sept. 27, 2022 — Critical Path Institute (C-Path) tod
September 22, 2022 View Now: Workshop: Accelerating Medical Product Development in Kidney Transplantation Through a Public-private Partnership C-Path’s Transplant Therapeutics Consortium (TTC), in collaboration with key opinion leaders from academic institutions, the pha
September 21, 2022 Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports
September 20, 2022 C-Path’s European Nonprofit Appoints Managing Director and New Board Member to Expand Global Efforts TUCSON, Ariz. and AMSTERDAM, September 20, 2022 — Critical Path Institute’s (C-Path) European nonprofit today announced the ap
September 15, 2022 Rare Disease Workshop Highlights the Importance of Data Sharing in Drug Development C-Path, NORD and FDA hosted an annual workshop September 13-14 to spotlight the impact of their innovative data and analytics plat
September 14, 2022 C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases TUCSON, Ariz., Sept. 14, 2022 — Critical Path Institute (C-Path) has announced it will serve as the convener of the Critical Pat
September 13, 2022-September 14, 2022 View Now | 2022 RDCA-DAP Workshop, September 13-14 Since its launch in 2019, the Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP®) has established i
